Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b randomized double-blind placebo-controlled study of sodium zirconium cyclosilicate in hyperkalemia among hemodialysis patients
2017-003029-14Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia comparing Sodium zirconium cyclosilicate with Placebo (2 arms). Primary endpoint: Proportion of patients who maintain target pre-dialysis serum potassium. Started Nov 2017; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2017-003029-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003029-14.